Angiomyofibroblastoma of the vagina in a breast cancer patient

Angiomyofibroblastoma of the uterine cervix in a breast cancer patient: A case report

“…A case of angiomyofi broblastoma related to tamoxifen treatment in a breast cancer patient was fi rst reported by Varras et al [10] The author assumed that tamoxifen may exert hormonal stimuli upon mesenchymal cells, resulting in the development of AMFB. Lee et al [11] presented a case of AMFB of vagina in a toremifene, a synthetic analogue of estrogen receptors, treated breast cancer patient. They suggested that toremifene treatment might have been causally related to the development of AMFB by the same reason of tamoxifen [11].…”

“…Lee et al [11] presented a case of AMFB of vagina in a toremifene, a synthetic analogue of estrogen receptors, treated breast cancer patient. They suggested that toremifene treatment might have been causally related to the development of AMFB by the same reason of tamoxifen [11]. There is also a domestic case report on vaginal AMFB in a breast cancer patient under tamoxifen treatment for 2 years by Bae et al [12]; however, the case study doesn't specify the relationship of Tamoxifen and AMFB.…”

Possible Relationship Between Tamoxifen Therapy and Vaginal Angiomyofibroblastoma

“…Our present case was on tamoxifen treatment as well for 18 months at a daily dose of 20 mg during the diagnosis of vaginal angiomyofibroblastoma and estrogen receptors were detected to be expressed immunohistochemically within the neoplastic cells. In 2008, Lee et al 3 reported another case of vaginal angiomyofibroblastoma which was detected in a woman who had a history of breast cancer and was treated with 40 mg/day oral toremifene for 3.5 years. Toremifene is a synthetic analogue of tamoxifen with fewer serious adverse effects.…”

“…1 The tumor predominantly arises in vulva while vaginal location is extremely rare and only 11 cases have been reported so far in the English literature. [2][3][4][5][6][7][8][9][10][11] We identified another case who had a history of infiltrative ductal carcinoma of breast and had undergone a left modified radical mastectomy 2 years ago followed by radiotherapy and combined chemotherapy consisting of cyclophosphamide and adriamycine. She was 37 years old during her admittance for routine gynaecologic examination when she was on tamoxifen therapy and monthly goserelin injections for 18 months.…”

“…10,[12][13][14] In an attempt to clarify the indeterminate etiopathogenesis of this rare entity, some of the recently published articles suggested a possible relation between development of angiomyofibroblastoma and use of selective est-rogen receptor modulators (SERMs). 3,7 Tamoxifen is the prototype of SERMs. It has clear anti-estrogenic effects on the breast and therefore is used orally for breast cancer treatment.…”